Announcement

Collapse
No announcement yet.

Efficacy of a specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Efficacy of a specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir

    Immunotherapy. 2016 Jul 5. [Epub ahead of print]
    Efficacy of a specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir.

    Herbreteau CH1, Denizot M1, Lowther S2, Riddell S2, Frazer L2, Haining J2, Arkinstall R2, Payne J2, Harper J2, Johnson D2, Pasquier A1, Middleton D2, Saluzzo JF1.
    Author information

    Abstract

    AIM:

    Current therapies against avian influenza (H5N1) provide limited clinical benefit. FBF-001 is a highly purified equine polyclonal immunoglobulin fragment against H5N1.
    METHODS:

    Using a ferret model of severe acute H5N1 infection, we assessed FBF-001 when administered on the same day or 1 day after viral challenge, in comparison with oseltamivir therapy.
    RESULTS:

    Untreated animals died 2-3 days after challenge. FBF-001 prevented most severe illness and reduced nasal viral load, with best efficacy when administered on the day of viral challenge. Oseltamivir and FBF-001 had synergistic impact on survival.
    CONCLUSION:

    FBF-001 prevented severe consequences of lethal H5N1 challenge in ferrets by controlling viral replication, an effect synergistic to oseltamivir. FBF-001 has recently been granted EMA orphan drug status.


    KEYWORDS:

    A/H5N1; F(ab')2; avian influenza; ferret; immunoglobulin; oseltamivir

    PMID: 27380317 DOI: 10.2217/imt-2016-0062
    [PubMed - as supplied by publisher]
Working...
X